ADVANCED SCIENCE & MACHINE LEARNING FOR HUMAN UNDERSTANDING
Selva Analytics LLC takes your research & development to the next level.
We are innovative and interdisciplinary, conducting research at the front lines of biology, finance, epidemiology, and more. We use cutting-edge statistics and machine learning, and often develop new tools to answer our clients' questions. We make the insights of your data available to you, translating machine learning into human understanding to translate data into decisions and products.
Microbiome Data Analysis
HARNESS THE MICROBIOME
We are at the front lines of method development in the microbiome space. With existing tools and trade secrets up our sleeves, your amplicon sequence and metagenomic datasets can be harnessed for discovery and product development.
Financial Data Analysis
DISCOVER THE SIGNAL
BEAT THE MARKET
Our team has developed new methods for data analysis in portfolio theory and has years of experience developing trading strategies based on analyses of comparative valuation of credit, equity, options, currencies, and financial derivatives prices in global markets. Whether quant, fundamental, or quantamental, our goal is to provide innovative insights that maximize alpha.
Biotech Venture Capital
FROM MICROBES TO MARKETS
In addition to on-the-ground experience with financial markets, we have decades of experience in biology, ranging from protein chemistry, immunology and physiology to the microbiome, metagenomics and epidemiology. This unique combination allows us to assess the value of intellectual property & trade secrets, the R&D potential of teams, the challenges bringing products to markets, and the near-term and long-term future of biotech.
PLANNING IN PANDEMICS
Throughout the COVID-19 pandemic, we've published some of the most impactful papers revealing the power of alternative data sources. From syndromic surveillance, sewage surveillance, to genomic surveillance discovering heightened transmissibility of B 1.1.7, we've been at the front-lines of COVID. Our forecasts predicted the March 2020 surge in NYC, the summer peaks of less-regulated US states, and currently we're actively monitoring India.